June 15, 2012 (Vol. 32, No. 12)
Promedior appointed Suzanne L. Bruhn, Ph.D., as president and CEO. Before joining Promedior, Dr. Bruhn was svp, strategic planning and program management for Shire’s human genetic therapies division. She also worked at Transkaryotic Therapies before Shire acquired it in 2005.
Organovo appointed Michael Renard to evp, commercial operations and promoted Sharon Collins Presnell, Ph.D., to evp, R&D, and CTO…China Biologic Products appointed Zhijun Tong and Sandy (Han) Zhangas as independent directors, Ming Yang as interim CFO, and promoted David (Xiaoying) Gao to the additional position of CEO…Robert Simon is now svp of regulatory affairs at Threshold Pharmaceuticals…PDL BioPharma appointed Bruce Tomlinson as vp and CFO…Durata Therapeutics elected Richard U. De Schutter as chairman of its board of directors…BioHealth Innovation added Douglas Liu to its board of directors.
Franck Barrat, Ph.D., joined Roche’s Inflammation Discovery and Translational Areas as a distinguished scientist. Dr. Barrat previously worked at Dynavax Technologies, most recently as senior research fellow and project leader of its autoimmunity program.
Population Genetics Technologies appointed Alan Schafer, Ph.D., as CEO…Liam Ratcliffe, M.D., Ph.D., was elected as independent director to Array BioPharma’s board of directors…Trinean appointed Philippe Stas as CEO…Regulus Therapeutics appointed Bruce Carter, Ph.D., to its board of directors…Althea Technologies hired Kristin DeFife, Ph.D., as director, biologics manufacturing and Jack Wright as vp, sales and marketing…Agios Pharmaceuticals appointed Robert J. DeVita, Ph.D., as vp, chemistry, Marion Dorsch, Ph.D., to vp, biology, and promoted John Evans to vp, business development and operations.
Michael R. Hayden, Ph.D., joined Teva Pharmaceutical Industries as president, global R&D and CSO. Dr. Hayden is Killam professor of medical genetics at the University of British Columbia. He is an expert on Huntington disease and has founded three biotechnology companies.
Keith McCormick joined Trovagene as head of commercial operations…Alnylam Pharmaceuticals elected Dennis A. Ausiello, M.D., to its board of directors and scientific advisory board…Knopp Biosciences hired Steven Boyd, Ph.D., as senior director of chemistry and Ian Reynolds, Ph.D., as senior director of biology…Pathway Genomics added James Fowler, Ph.D., Christoph Lange, Ph.D., and Nicholas Schork, Ph.D., to its scientific advisory board…Avaxia Biologics elected Christopher Kiritsy to its board of directors…Versartis named Edmon R. Jennings chairman of its board of directors.
Oxford BioTherapeutics hired Esteban Pombo-Villar, Ph.D., as COO of the OBT group. Dr. Pombo-Villar previously worked at Novartis for over 20 years, most recently as head of alliance management at the Novartis Institute for Biomedical Research.
Lantheus Medical Imaging hired Alexander (Alex) E. Kuta, Ph.D., as vp, global regulatory affairs, and Nigel Williams as vp, quality…Peptides International appointed Timothy (“Tim”) Morgan as sales manager…Albany Molecular Research added William S. Marth to its board of directors…Theorem Clinical Research named Edward Ian executive director, clinical development, for the Asia-Pacific region within its Taipei, Taiwan, office…Thomas M. Moriarty is now general counsel and corporate secretary of Celgene.
Prisca Havranek-Kosicek, Ph.D., is now CFO of DSM Pharmaceutical Products. Dr. Havranek-Kosicek was previously director of finance and control for DSM Pharmaceutical Products’ DSM Pharma Chemicals business unit. Before joining DSM, Dr. Havranek-Kosicek worked at Immofinanz.
Banyan Biomarkers elected Andrew von Eschenbach, M.D., to its board of directors…BioMarin appointed Dan Spiegelman as evp and CFO…George Demetri, M.D., joined Blueprint Medicines as a clinical advisor…InnoPharma hired John C. Deighan as CFO…Cytovance Biologics appointed Martin LeBlanc to its board of directors.
Send your People Announcements to firstname.lastname@example.org.